Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas

Steffen Weikert(St. Hedwig-Krankenhaus), Hans Krause(Charité - Universitätsmedizin Berlin), Jens Köllermann, Markus Müller(Charité - Universitätsmedizin Berlin), Mark Schrader(Arbeitsgemeinschaft Urologische Onkologie), Kurt Miller(Charité - Universitätsmedizin Berlin), Frank Christoph(Charité - Universitätsmedizin Berlin)

International Journal of Molecular Medicine

August 1, 2005

10.3892/ijmm.16.2.349

Cited by 151

Related Papers

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

|New England Journal of Medicine|2014|3k

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

|The Lancet Oncology|2015|1.4k

The Epidemiology of Renal Cell Carcinoma

|European Urology|2011|1k

Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study

|European Urology|2016|414

IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial

|The Lancet Oncology|2016|218